CVS Caremark Hits New 12-Month High at $80.48 (CVS)
CVS Caremark (NYSE:CVS) reached a new 52-week high during mid-day trading on Wednesday , ARN reports. The company traded as high as $80.48 and last traded at $80.46, with a volume of 1,860,050 shares. The stock had previously closed at $79.73.
CVS has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of CVS Caremark in a research note on Tuesday, August 12th. They now have a $82.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of CVS Caremark in a research note on Wednesday, August 6th. They now have a $91.00 price target on the stock, up previously from $82.00. Finally, analysts at Cantor Fitzgerald raised their price target on shares of CVS Caremark from $66.00 to $71.00 in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $78.90.
The stock has a 50-day moving average of $78.24 and a 200-day moving average of $75.78. The company has a market cap of $93.403 billion and a P/E ratio of 19.55.
CVS Caremark (NYSE:CVS) last announced its earnings results on Tuesday, August 5th. The company reported $1.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.03. The company had revenue of $34.60 billion for the quarter, compared to the consensus estimate of $33.47 billion. During the same quarter in the previous year, the company posted $0.97 earnings per share. The company’s revenue for the quarter was up 10.7% on a year-over-year basis. On average, analysts predict that CVS Caremark will post $4.49 earnings per share for the current fiscal year.
CVS Caremark Corporation (NYSE:CVS), together with its subsidiaries, is a pharmacy health care provider in the United States.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.